3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
59
Squamous Cell Carcinoma of Head and Neck
32
Carcinoma, Non-Small-Cell Lung
29
Neoplasms
26
Head and Neck Neoplasms
26
Colonic Neoplasms
20
Neoplasm Metastasis
17
Rectal Neoplasms
12
Breast Neoplasms
11
Lung Neoplasms
10
Pancreatic Neoplasms
9
Carcinoma, Squamous Cell
6
Tongue Neoplasms
5
Salivary Gland Neoplasms
5
Melanoma
5
Stomach Neoplasms
4
Solid Tumors
4
Ovarian Neoplasms
4
Carcinoma, Renal Cell
4
Advanced Solid Tumor
4
Triple Negative Breast Neoplasms
3
Sarcoma
3
Kidney Neoplasms
3
Endometrial Neoplasms
3
Advanced Cancers
3
Uterine Cervical Neoplasms
2
Thyroid Neoplasms
2
Recurrence
2
Pharyngeal Neoplasms
2
Neoplasms by Site
2
Interventions
Imatinib Mesylate
2
spartalizumab
1
pembrolizumab
1
nilotinib
1
Thiotepa
1
Radiotherapy
1
Radiosurgery
1
Photochemotherapy
1
Peripheral Blood Stem Cell Transplantation
1
Pemetrexed
1
Panobinostat
1
Nivolumab
1
Melphalan
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Dihematoporphyrin Ether
1
Cyclophosphamide
1
Cetuximab
1
Busulfan
1
Bone Marrow Transplantation
1
Blood Specimen Collection
1
Bacterial Load
1
Amifostine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Chordoma
×
Cetuximab
×
Clear all
NCT04670679
2026-03-25
FLAGSHP-1
Erasca, Inc.
Phase 1
Active not recruiting
90 enrolled